All In Biotech

Drug Trial Radar · NCT03332771

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy

Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 954 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

954

Actual

Start

Dec 1, 2017

Primary completion

Aug 6, 2019

Study completion Sep 6, 2019

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin. Secondary Objectives: To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter \[mg/dL\]). * To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all participants. * To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in HbA1c. * To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and placebo.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Sotagliflozin (SAR439954)Drug

    Pharmaceutical form: tablet Route of administration: oral

  • GlimepirideDrug

    Pharmaceutical form: capsule Route of administration: oral

  • MetforminDrug

    Pharmaceutical form: tablet Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: tablet Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c at Week 52Time frame: Baseline, Week 52

Locations

142 sites in 4 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8407040

    Birmingham, Alabama

  • Investigational Site Number 8407048

    Birmingham, Alabama

  • Investigational Site Number 8407035

    Little Rock, Arkansas

  • Investigational Site Number 8407051

    Anaheim, California

  • Investigational Site Number 8407065

    Canoga Park, California

  • Investigational Site Number 8407078

    Carmichael, California

  • Investigational Site Number 8407089

    Downey, California

  • Investigational Site Number 8407011

    Gold River, California

  • Investigational Site Number 8407044

    Greenbrae, California

  • Investigational Site Number 8407006

    Huntington Park, California

  • Investigational Site Number 8407037

    Lemon Grove, California

  • Investigational Site Number 8407100

    Lomita, California

  • Investigational Site Number 8407033

    Long Beach, California

  • Investigational Site Number 8407019

    Los Angeles, California

  • Investigational Site Number 8407098

    Northridge, California

  • Investigational Site Number 8407094

    Norwalk, California

  • Investigational Site Number 8407106

    Pomona, California

  • Investigational Site Number 8407096

    Rancho Cucamonga, California

  • Investigational Site Number 8407036

    Sacramento, California

  • Investigational Site Number 8407084

    Tarzana, California

  • Investigational Site Number 8407034

    Upland, California

  • Investigational Site Number 8407032

    Van Nuys, California

  • Investigational Site Number 8407004

    Walnut Creek, California

  • Investigational Site Number 8407117

    Wildomar, California

  • Investigational Site Number 8407045

    Colorado Springs, Colorado

  • Investigational Site Number 8407074

    Bradenton, Florida

  • Investigational Site Number 8407027

    Clearwater, Florida

  • Investigational Site Number 8407103

    Cooper City, Florida

  • Investigational Site Number 8407021

    Coral Gables, Florida

  • Investigational Site Number 8407062

    Lake Worth, Florida

  • Investigational Site Number 8407121

    Ocoee, Florida

  • Investigational Site Number 8407024

    Orlando, Florida

  • Investigational Site Number 8407038

    Palmetto Bay, Florida

  • Investigational Site Number 8407093

    Pembroke Pines, Florida

  • Investigational Site Number 8407107

    Spring Hill, Florida

  • Investigational Site Number 8407091

    Tampa, Florida

  • Investigational Site Number 8407113

    Tampa, Florida

  • Investigational Site Number 8407092

    West Palm Beach, Florida

  • Investigational Site Number 8407115

    Winter Haven, Florida

  • Investigational Site Number 8407017

    Chicago, Illinois

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.